Saba Capital Reveals 5.1% Stake in BCAT via $78M Schedule 13D Filing

Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein jointly filed Amendment No. 21 to their Schedule 13D on BlackRock Capital Allocation Term Trust (ticker BCAT).

Rhea-AI Filing Summary

Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein jointly filed Amendment No. 21 to their Schedule 13D on BlackRock Capital Allocation Term Trust (ticker BCAT).

• Ownership disclosed: 5,352,474 – 5,352,475 common shares, equal to 5.11 % of the 104,775,271 shares outstanding as of 5/19/25.
• Voting/Dispositive power: 0 sole; full power is shared among the reporting persons.
• Cost basis: approximately $78.4 million in aggregate consideration, funded with investor capital and ordinary-course margin borrowings.
• Transaction window: open-market purchases between 7/14/25 and 7/24/25 prompted the filing.
• Purpose of transaction: “Not Applicable”; no specific strategic intentions or agreements were disclosed (Items 4 & 6).

The filing converts the group from passive (13G) to active (13D) status and updates Items 3, 5 and 7. No criminal or civil proceedings are reported against the filers, and signature authority is provided by General Counsel Michael D’Angelo.

Insights

Portfolio Manager

TL;DR: Saba’s filing shows a new 5.1 % position in BCAT; no stated agenda but 13D status suggests optional activism.

The switch from a 13G to a 13D indicates Saba now reserves the right to influence BCAT. Although no plans were detailed, accumulating a >5 % stake worth $78 million positions the hedge fund to pressure management on discount-to-NAV issues common in closed-end funds. The ownership is shared across Saba-managed funds, giving them voting leverage without sole control. For investors, the entry of an experienced credit CEF specialist can act as a catalyst for narrowing discounts, but the absence of an explicit campaign tempers immediate impact.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BCAT shares does Saba Capital now own?

The filing reports 5,352,474–5,352,475 common shares, equal to 5.11 % of shares outstanding.

What was the cost of Saba’s BCAT position?

Approximately $78.4 million in aggregate purchase consideration.

Why did Saba file a Schedule 13D instead of 13G?

Owning more than 5 % and switching to a 13D allows Saba to take actions that may influence BCAT, though no plans were disclosed.

Does Saba have sole voting power over the BCAT shares?

No. The filing states 0 sole voting/dispositive power; all power is shared among the reporting persons.

When were the latest BCAT purchases made by Saba?

Open-market transactions occurred between 7/14/25 and 7/24/25.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/28/2025 - 05:52 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 21)

BlackRock Capital Allocation Term Trust

(Name of Issuer)

Common Shares, $0.001 par value

(Title of Class of Securities)

09260U109

(CUSIP Number)

Saba Capital Management, L.P.
405 Lexington Avenue, 58th Floor, Attention: Michael D'Angelo
New York, NY, 10174
(212) 542-4635

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

07/24/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 09260U109

1

Name of reporting person

Saba Capital Management, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,352,474.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,352,474.00

11

Aggregate amount beneficially owned by each reporting person

5,352,474.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.11 %

14

Type of Reporting Person (See Instructions)

PN, IA

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 104,775,271 shares of common stock outstanding as of 5/19/25, as disclosed in the company's DEF 14A filed with the Securities and Exchange Commission on 5/22/25.

SCHEDULE 13D

CUSIP No. 09260U109

1

Name of reporting person

Boaz R. Weinstein

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,352,475.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,352,475.00

11

Aggregate amount beneficially owned by each reporting person

5,352,475.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.11 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 104,775,271 shares of common stock outstanding as of 5/19/25, as disclosed in the company's DEF 14A filed with the Securities and Exchange Commission on 5/22/25.

SCHEDULE 13D

CUSIP No. 09260U109

1

Name of reporting person

Saba Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 5,352,474.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 5,352,474.00

11

Aggregate amount beneficially owned by each reporting person

5,352,474.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

5.11 %

14

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person:

The percentages used herein are calculated based upon 104,775,271 shares of common stock outstanding as of 5/19/25, as disclosed in the company's DEF 14A filed with the Securities and Exchange Commission on 5/22/25.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Shares, $0.001 par value
(b)	Name of Issuer: BlackRock Capital Allocation Term Trust
(c)	Address of Issuer's Principal Executive Offices: 100 Bellevue Parkway, Wilmington, DELAWARE , 19809.
Item 1 Comment: This Amendment No. 21 amends Items 3, 5, and 7.
Item 2.	Identity and Background
(a)	This Schedule 13D/A is being jointly filed by: (i) Saba Capital Management, L.P., a Delaware limited partnership ("Saba Capital"); (ii) Saba Capital Management GP, LLC, a Delaware limited liability company ("Saba GP"); and (iii) Mr. Boaz R. Weinstein ("Mr. Weinstein"), (together, the "Reporting Persons"). Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party. The filing of this statement should not be construed as an admission that any Reporting Person is, for the purposes of Sections 13 of the Securities Exchange Act of 1934, the beneficial owner of the Common Shares reported herein.
(b)	The address of the business office of each of the Reporting Persons is 405 Lexington Avenue, 58th Floor, New York, New York 10174.
(c)	The principal business of: (i) Saba Capital is to serve as investment manager to private and public investment funds and/or accounts, (ii) Saba GP is to serve as general partner of the Saba Capital and other affiliated entities, and (iii) Mr. Weinstein, an individual, is managing member of the general partner of Saba Capital and other affiliated entities.
(d)	The Reporting Persons have not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	The Reporting Persons have not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws.
(f)	Saba Capital is organized as a limited partnership under the laws of the State of Delaware. Saba GP is organized as a limited liability company under the laws of the State of Delaware. Mr. Weinstein is a citizen of the United States.
Item 3.	Source and Amount of Funds or Other Consideration
	Funds for the purchase of the Common Shares were derived from the subscription proceeds from investors and the capital appreciation thereon and margin account borrowings made in the ordinary course of business. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the account, which may exist from time to time. Since other securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Common Shares reported herein. A total of approximately $78,417,581 was paid to acquire the Common Shares reported herein.
Item 4.	Purpose of Transaction
	Not Applicable.
Item 5.	Interest in Securities of the Issuer
(a)	See the Reporting Persons section of this Schedule 13D/A for the aggregate number of Common Shares and percentages of the Common Shares beneficially owned by each of the Reporting Persons. The percentages used herein are calculated based upon 104,775,271 shares of common stock outstanding as of 5/19/25, as disclosed in the company's DEF 14A filed with the Securities and Exchange Commission on 5/22/25.
(b)	See the Reporting Persons section of this Schedule 13D/A for the number of Common Shares as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
(c)	The transactions in the Common Shares effected from the filing of the Schedule 13D/A on 7/14/25 by the Reporting Persons to 7/24/25, the date of the event which required filing of this Schedule 13D/A, which were all in the open market, are set forth in Schedule A, and are incorporated herein by reference.
(d)	The funds and accounts advised by Saba Capital have the right to receive the dividends and proceeds of sales from the Common Shares.
(e)	Not Applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not Applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 14 - Schedule A

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Saba Capital Management, L.P.

Signature:	/s/ Michael D'Angelo
Name/Title:	General Counsel
Date:	07/28/2025

Boaz R. Weinstein

Signature:	/s/ Michael D'Angelo
Name/Title:	Authorized Signatory
Date:	07/28/2025

Saba Capital Management GP, LLC

Signature:	/s/ Michael D'Angelo
Name/Title:	Attorney-in-fact*
Date:	07/28/2025

Comments accompanying signature:

Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823